HIV PreventionResearch & Development Investment in 2013 In a changing global development, economic, and

human rights landscape

Presented at the International AIDS & Economics Network Pre-conference, Melbourne, July 2014

Emily Donaldson, AVACPresenting on behalf of the HIV Vaccines & Microbicides Resource Tracking Working Group

Methodology• Comprehensive and consistent investment data collection and

disaggregation methodology since 2004• Data collection January – June 2014

HIV Vaccines & Microbicides Resource Tracking Working Group

• Data Sources:• Public funders (447 grants)

• Philanthropic (141 grants)

• Industry (7 grants)

• R&D Categories:• Preventive HIV vaccines (307 grants)

• Microbicides (84 grants)

• Pre-exposure prophylaxis (54 grants)

• Treatment as prevention (80 grants)

• Male circumcision (20 grants)

• Female condom (4 grants)

• Prevention of vertical transmission (24 grants)

• HSV-2 vaccines (22 grants)

• HIV cure (150 grants)

• Therapeutic HIV vaccines (45 grants)

2009 2010 2011 2012 2013$0

$200

$400

$600

$800

$1,000

$1,200

Female Condoms Prevention of Vertical Transmission Treatment as Prevention*

Adult Male Circumcision Pre-exposure Prophylaxis Microbicides

Preventive Vaccines

Global HIV Prevention R&D Investment, 2009 – 2013(US$ millions)

US$1.26BUS$1.31BUS$1.28BUS$1.27BUS$1.22B

HIV Vaccines & Microbicides Resource Tracking Working Group

Global HIV Prevention R&D Investment 2013 by Funder Type(US$ millions)

887; 70%

77; 6%

65; 5%

193; 15%

37; 3%

US Public-Sector European Public-Sector Other Governments

Philanthropic Industry

HIV Vaccines & Microbicides Resource Tracking Working Group

Global HIV Prevention R&D Investment 2012 & 2013(US$ millions)

Funding Source Amount 2013 Amount 2012 % Change from 2012

US Public-Sector 887 925 -4%

European Public-Sector

77 86 -10%

Other Governments

65 69 -6%

Philanthropic 193 203 -5%

Industry 37 34 +9%

All HIV Prevention R&D

1.26 1.31 -4%

HIV Vaccines & Microbicides Resource Tracking Working Group

2013 Investment and Year-Over-Year Change

HIV Vaccines & Microbicides Resource Tracking Working Group

$154M

2013 International Development Funding

HIV Vaccines & Microbicides Resource Tracking Working Group

Global HIV Prevention R&D Investment 2013 by Prevention Option(US$ millions)

818; 65%210; 17%

36; 3% 117; 9%

32; 3%

2; 0%44; 3%

Preventive HIV Vaccines Microbicides Pre-exposure Prophylaxis Treatment as Prevention

Male circumcision Female Condom Prevention of vertical transmission

HIV Vaccines & Microbicides Resource Tracking Working Group

Global HIV Prevention R&D Investment 2012 & 2013(US$ millions)

HIV Prevention Option

Amount 2013 Amount 2012 % Change from 2012

Preventive HIV vaccines

818 847 -3%

Microbicides 210 245 -14%

Pre-exposure Prophylaxis

36 31 +16%

Treatment as Prevention

117 98 +19%

Male circumcision 32 41.6 -23%

Female condoms 2.2 2 +10%

Prevention of vertical transmission

44 43.8 +0.5%

All HIV Prevention R&D

1.26 1.31 -4%

HIV Vaccines & Microbicides Resource Tracking Working Group

HIV Prevention Trial Participants by Region 2013

Advocacy, policy and funding trends

• The US public sector funds the majority of HIV prevention R&D.

• Philanthropic organizations increasingly fund vital parts of HIV prevention research.

• Industry funding stayed almost flat and shifted to later development stages.

• International development priorities are evolving.

• The enabling environment has a profound effect on where trials take place and whether they are able to happen.

HIV Vaccines & Microbicides Resource Tracking Working Group

Acknowledgements

Significant contributions from the Working Group organizations, AVAC, the International AIDS Vaccine Initiative (IAVI), and the Joint United Nations Programme on HIV/AIDS (UNAIDS) and Working Group members Kevin Fisher (AVAC), Reuben Granich (UNAIDS), Thomas Harmon (IAVI), Polly Harrison (AVAC) and Mitchell Warren (AVAC).

For the full report, including graphics and past reports, visit www.hivresourcetracking.org